Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders.

Steen NE, Dieset I, Hope S, Vedal TSJ, Smeland OB, Matson W, Kaddurah-Daouk R, Agartz I, Melle I, Djurovic S, Jönsson EG, Bogdanov M, Andreassen OA.

Psychol Med. 2019 Mar 14:1-12. doi: 10.1017/S0033291719000400. [Epub ahead of print]

PMID:
30867076
2.

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics.

Liu D, Ray B, Neavin DR, Zhang J, Athreya AP, Biernacka JM, Bobo WV, Hall-Flavin DK, Skime MK, Zhu H, Jenkins GD, Batzler A, Kalari KR, Boakye-Agyeman F, Matson WR, Bhasin SS, Mushiroda T, Nakamura Y, Kubo M, Iyer RK, Wang L, Frye MA, Kaddurah-Daouk R, Weinshilboum RM.

Transl Psychiatry. 2018 Jan 10;8(1):10. doi: 10.1038/s41398-017-0056-8.

3.

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.

Gupta M, Neavin D, Liu D, Biernacka J, Hall-Flavin D, Bobo WV, Frye MA, Skime M, Jenkins GD, Batzler A, Kalari K, Matson W, Bhasin SS, Zhu H, Mushiroda T, Nakamura Y, Kubo M, Wang L, Kaddurah-Daouk R, Weinshilboum RM.

Mol Psychiatry. 2016 Dec;21(12):1717-1725. doi: 10.1038/mp.2016.6. Epub 2016 Feb 23.

4.

A systems-level "misunderstanding": the plasma metabolome in Huntington's disease.

Rosas HD, Doros G, Bhasin S, Thomas B, Gevorkian S, Malarick K, Matson W, Hersch SM.

Ann Clin Transl Neurol. 2015 Jul;2(7):756-68. doi: 10.1002/acn3.214. Epub 2015 May 28.

5.

Metabolomics analysis reveals insights into biochemical mechanisms of mental stress-induced left ventricular dysfunction.

Boyle SH, Matson WR, Velazquez EJ, Samad Z, Williams RB Jr, Sharma S, Thomas B, Wilson JL, O'Connor C, Jiang W.

Metabolomics. 2015 Jun 1;11(3):571-582.

6.

Associations between central nervous system serotonin, fasting glucose, and hostility in African American females.

Boyle SH, Georgiades A, Brummett BH, Barefoot JC, Siegler IC, Matson WR, Kuhn CM, Grichnik K, Stafford-Smith M, Williams RB, Kaddurah-Daouk R, Surwit RS.

Ann Behav Med. 2015 Feb;49(1):49-57. doi: 10.1007/s12160-014-9626-7.

7.

Identification of metabolites from liquid chromatography-coulometric array detection profiling: gas chromatography-mass spectrometry and refractionation provide essential information orthogonal to LC-MS/microNMR.

Gathungu RM, Bird SS, Sheldon DP, Kautz R, Vouros P, Matson WR, Kristal BS.

Anal Biochem. 2014 Jun 1;454:23-32. doi: 10.1016/j.ab.2014.01.020. Epub 2014 Mar 18.

8.

PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease.

Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu JP, Triggs TD, Wilkens PJ, Matson W, Salat DH, Hersch SM.

Neurology. 2014 Mar 11;82(10):850-7. doi: 10.1212/WNL.0000000000000187. Epub 2014 Feb 7.

9.

Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging.

Motsinger-Reif AA, Zhu H, Kling MA, Matson W, Sharma S, Fiehn O, Reif DM, Appleby DH, Doraiswamy PM, Trojanowski JQ, Kaddurah-Daouk R, Arnold SE.

Acta Neuropathol Commun. 2013 Jun 27;1:28. doi: 10.1186/2051-5960-1-28.

10.

HTRF analysis of soluble huntingtin in PHAROS PBMCs.

Moscovitch-Lopatin M, Goodman RE, Eberly S, Ritch JJ, Rosas HD, Matson S, Matson W, Oakes D, Young AB, Shoulson I, Hersch SM; Huntington Study Group PHAROS Investigators.

Neurology. 2013 Sep 24;81(13):1134-40. doi: 10.1212/WNL.0b013e3182a55ede. Epub 2013 Aug 21.

11.

Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway.

Zhu H, Bogdanov MB, Boyle SH, Matson W, Sharma S, Matson S, Churchill E, Fiehn O, Rush JA, Krishnan RR, Pickering E, Delnomdedieu M, Kaddurah-Daouk R; Pharmacometabolomics Research Network.

PLoS One. 2013 Jul 17;8(7):e68283. doi: 10.1371/journal.pone.0068283. Print 2013.

12.

Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis.

Yao JK, Dougherty GG, Reddy RD, Matson WR, Kaddurah-Daouk R, Keshavan MS.

Front Cell Neurosci. 2013 Jun 11;7:90. doi: 10.3389/fncel.2013.00090. eCollection 2013.

13.

Alterations in metabolic pathways and networks in Alzheimer's disease.

Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, Oki NO, Motsinger-Reif AA, Churchill E, Lei Z, Appleby D, Kling MA, Trojanowski JQ, Doraiswamy PM, Arnold SE; Pharmacometabolomics Research Network.

Transl Psychiatry. 2013 Apr 9;3:e244. doi: 10.1038/tp.2013.18.

14.

A novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease.

Thomas B, Matson S, Chopra V, Sun L, Sharma S, Hersch S, Rosas HD, Scherzer C, Ferrante R, Matson W.

Anal Biochem. 2013 May 15;436(2):112-20. doi: 10.1016/j.ab.2013.01.035. Epub 2013 Feb 12.

15.

Structural characterization of plasma metabolites detected via LC-electrochemical coulometric array using LC-UV fractionation, MS, and NMR.

Bird SS, Sheldon DP, Gathungu RM, Vouros P, Kautz R, Matson WR, Kristal BS.

Anal Chem. 2012 Nov 20;84(22):9889-98. doi: 10.1021/ac302278u. Epub 2012 Nov 6.

16.

Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile.

Kaddurah-Daouk R, Yuan P, Boyle SH, Matson W, Wang Z, Zeng ZB, Zhu H, Dougherty GG, Yao JK, Chen G, Guitart X, Carlson PJ, Neumeister A, Zarate C, Krishnan RR, Manji HK, Drevets W.

Sci Rep. 2012;2:667. Epub 2012 Sep 19.

17.

Associations between purine metabolites and clinical symptoms in schizophrenia.

Yao JK, Condray R, Dougherty GG Jr, Keshavan MS, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R, Reddy RD.

PLoS One. 2012;7(8):e42165. doi: 10.1371/journal.pone.0042165. Epub 2012 Aug 14.

18.

A high-throughput screen to identify inhibitors of SOD1 transcription.

Wright PD, Wightman N, Huang M, Weiss A, Sapp PC, Cuny GD, Ivinson AJ, Glicksman MA, Ferrante RJ, Matson W, Matson S, Brown RH Jr.

Front Biosci (Elite Ed). 2012 Jun 1;4:2701-8.

19.

8OHdG as a marker for Huntington disease progression.

Long JD, Matson WR, Juhl AR, Leavitt BR, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Neurobiol Dis. 2012 Jun;46(3):625-34. doi: 10.1016/j.nbd.2012.02.012. Epub 2012 Mar 5.

20.

Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10.

Biglan KM, Dorsey ER, Evans RV, Ross CA, Hersch S, Shoulson I, Matson W, Kieburtz K; Huntington Study Group Pre-2CARE Investigators.

J Huntingtons Dis. 2012;1(1):65-9. doi: 10.3233/JHD-2012-120007.

21.

Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept.

Kaddurah-Daouk R, Boyle SH, Matson W, Sharma S, Matson S, Zhu H, Bogdanov MB, Churchill E, Krishnan RR, Rush AJ, Pickering E, Delnomdedieu M.

Transl Psychiatry. 2011;1. pii: e26. doi: 10.1038/tp.2011.22.

22.

Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse.

Hu Y, Chopra V, Chopra R, Locascio JJ, Liao Z, Ding H, Zheng B, Matson WR, Ferrante RJ, Rosas HD, Hersch SM, Scherzer CR.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17141-6. doi: 10.1073/pnas.1104409108. Epub 2011 Oct 3.

23.

3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.

Condray R, Dougherty GG Jr, Keshavan MS, Reddy RD, Haas GL, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R, Yao JK.

Int J Neuropsychopharmacol. 2011 Jul;14(6):756-67. doi: 10.1017/S1461145710001689. Epub 2011 Jan 28.

24.

Patterns in a suspension contained in a horizontally rotating cylinder.

Matson WR, Ackerson BJ, Tong P.

Chaos. 2010 Dec;20(4):041102. doi: 10.1063/1.3491340. No abstract available.

PMID:
21198063
25.

Metabolomic changes in autopsy-confirmed Alzheimer's disease.

Kaddurah-Daouk R, Rozen S, Matson W, Han X, Hulette CM, Burke JR, Doraiswamy PM, Welsh-Bohmer KA.

Alzheimers Dement. 2011 May;7(3):309-17. doi: 10.1016/j.jalz.2010.06.001. Epub 2010 Nov 13.

26.

Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease.

Kim J, Amante DJ, Moody JP, Edgerly CK, Bordiuk OL, Smith K, Matson SA, Matson WR, Scherzer CR, Rosas HD, Hersch SM, Ferrante RJ.

Biochim Biophys Acta. 2010 Jul-Aug;1802(7-8):673-81. doi: 10.1016/j.bbadis.2010.05.001. Epub 2010 May 9.

27.

Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia.

Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R.

PLoS One. 2010 Mar 3;5(3):e9508. doi: 10.1371/journal.pone.0009508.

28.

Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry.

Ebbel EN, Leymarie N, Schiavo S, Sharma S, Gevorkian S, Hersch S, Matson WR, Costello CE.

Anal Biochem. 2010 Apr 15;399(2):152-61. doi: 10.1016/j.ab.2010.01.010. Epub 2010 Jan 13.

29.

Metabolomic profiling in LRRK2-related Parkinson's disease.

Johansen KK, Wang L, Aasly JO, White LR, Matson WR, Henchcliffe C, Beal MF, Bogdanov M.

PLoS One. 2009 Oct 22;4(10):e7551. doi: 10.1371/journal.pone.0007551.

30.

Urate as a predictor of the rate of clinical decline in Parkinson disease.

Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA; Parkinson Study Group DATATOP Investigators.

Arch Neurol. 2009 Dec;66(12):1460-8. doi: 10.1001/archneurol.2009.247.

31.

Opioid use affects antioxidant activity and purine metabolism: preliminary results.

Mannelli P, Patkar A, Rozen S, Matson W, Krishnan R, Kaddurah-Daouk R.

Hum Psychopharmacol. 2009 Dec;24(8):666-75. doi: 10.1002/hup.1068.

32.

Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study.

Patkar AA, Rozen S, Mannelli P, Matson W, Pae CU, Krishnan KR, Kaddurah-Daouk R.

Psychopharmacology (Berl). 2009 Oct;206(3):479-89. doi: 10.1007/s00213-009-1625-1. Epub 2009 Aug 1.

PMID:
19649617
33.

Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia.

Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R.

Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28.

34.

Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants.

Stack EC, Matson WR, Ferrante RJ.

Ann N Y Acad Sci. 2008 Dec;1147:79-92. doi: 10.1196/annals.1427.008. Review.

PMID:
19076433
35.

Metabolomic analysis and signatures in motor neuron disease.

Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C, Harrison S, Vouros P, Flarakos J, Vigneau-Callahan K, Matson TD, Newhall KM, Beal MF, Brown RH Jr, Kaddurah-Daouk R.

Metabolomics. 2005;1(2):101-108.

36.

Phase 2 study of sodium phenylbutyrate in ALS.

Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH Jr, Zhang H, Schoenfeld DA, Shefner J, Matson S, Matson WR, Ferrante RJ; Northeast ALS and National VA ALS Research Consortiums.

Amyotroph Lateral Scler. 2009 Apr;10(2):99-106. doi: 10.1080/17482960802320487.

PMID:
18688762
37.

Metabolite identification using a nanoelectrospray LC-EC-array-MS integrated system.

Schiavo S, Ebbel E, Sharma S, Matson W, Kristal BS, Hersch S, Vouros P.

Anal Chem. 2008 Aug 1;80(15):5912-23. doi: 10.1021/ac800507y. Epub 2008 Jun 25.

38.

Increased levels of gamma-glutamylamines in Huntington disease CSF.

Jeitner TM, Matson WR, Folk JE, Blass JP, Cooper AJ.

J Neurochem. 2008 Jul;106(1):37-44. doi: 10.1111/j.1471-4159.2008.05350.x. Epub 2008 Jul 1.

39.

Metabolomic profiling to develop blood biomarkers for Parkinson's disease.

Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Flint Beal M.

Brain. 2008 Feb;131(Pt 2):389-96. doi: 10.1093/brain/awm304.

PMID:
18222993
40.

Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease.

Stack EC, Ferro JL, Kim J, Del Signore SJ, Goodrich S, Matson S, Hunt BB, Cormier K, Smith K, Matson WR, Ryu H, Ferrante RJ.

Biochim Biophys Acta. 2008 Mar;1782(3):151-62. doi: 10.1016/j.bbadis.2007.12.006. Epub 2008 Jan 16.

41.

Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice.

Stack EC, Dedeoglu A, Smith KM, Cormier K, Kubilus JK, Bogdanov M, Matson WR, Yang L, Jenkins BG, Luthi-Carter R, Kowall NW, Hersch SM, Beal MF, Ferrante RJ.

J Neurosci. 2007 Nov 21;27(47):12908-15.

42.

Biological variability dominates and influences analytical variance in HPLC-ECD studies of the human plasma metabolome.

Shurubor YI, Matson WR, Willett WC, Hankinson SE, Kristal BS.

BMC Clin Pathol. 2007 Nov 12;7:9.

43.

A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.

Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, Housman DE, Kazantsev A, Young AB, Hersch S.

Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16685-9. Epub 2007 Oct 9.

44.

Metabolomics in the study of aging and caloric restriction.

Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR.

Methods Mol Biol. 2007;371:393-409. Review.

PMID:
17634593
45.

High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics.

Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR.

Methods Mol Biol. 2007;358:159-74.

PMID:
17035686
46.

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.

Smith KM, Matson S, Matson WR, Cormier K, Del Signore SJ, Hagerty SW, Stack EC, Ryu H, Ferrante RJ.

Biochim Biophys Acta. 2006 Jun;1762(6):616-26. Epub 2006 Apr 17.

47.

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, Como P, Zimmerman C, Lin M, Zhang L, Ulug AM, Beal MF, Matson W, Bogdanov M, Ebbel E, Zaleta A, Kaneko Y, Jenkins B, Hevelone N, Zhang H, Yu H, Schoenfeld D, Ferrante R, Rosas HD.

Neurology. 2006 Jan 24;66(2):250-2.

PMID:
16434666
48.

Increased oxidative damage to DNA in an animal model of amyotrophic lateral sclerosis.

Aguirre N, Beal MF, Matson WR, Bogdanov MB.

Free Radic Res. 2005 Apr;39(4):383-8.

PMID:
16028363
49.

Concentration and velocity patterns in a horizontal rotating suspension of non-Brownian settling particles.

Matson WR, Kalyankar M, Ackerson BJ, Tong P.

Phys Rev E Stat Nonlin Soft Matter Phys. 2005 Mar;71(3 Pt 1):031401. Epub 2005 Mar 22.

PMID:
15903425
50.

Development of biomarkers based on diet-dependent metabolic serotypes: characteristics of component-based models of metabolic serotypes.

Paolucci U, Vigneau-Callahan KE, Shi H, Matson WR, Kristal BS.

OMICS. 2004 Fall;8(3):221-38.

PMID:
15669715

Supplemental Content

Loading ...
Support Center